For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Metolazone - Hypertension
PAD Profile : Metolazone - Hypertension
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Aliskiren
- Bendroflumethiazide
- Candesartan cilexetil
- Eprosartan
- Indapamide
- Irbesartan
- Losartan potassium
- Olmesartan medoxomil
- Valsartan
- Ramipril
- Amlodipine
- Lisinopril
- Bisoprolol fumarate
- Doxazosin mesilate
- Diltiazem hydrochloride
- Nifedipine
- Perindopril erbumine
- Telmisartan
- Moxonidine
- Co-tenidone (Atenolol/chlortalidone)
- Enalapril maleate
- Quinapril hydrochloride
- Nebivolol
- Perindopril arginine
- Azilsartan medoxomil
- Captopril
- Lercanidipine hydrochloride
- Nicardipine hydrochloride
- Chlortalidone
- Spironolactone
- Atenolol
- Carvedilol
- Celiprolol hydrochloride
- Metoprolol tartrate
- Propranolol hydrochloride
- Prazosin hydrochloride
- Clonidine hydrochloride
- Hydralazine hydrochloride
Other Indications
Additional Documents
Committee Recommendations
Although there may have been historic prescribing of metolazone for hypertension in parts of Surrey, metolazone has not been formally assessed for this indication in Surrey Heartlands. Prescribing for hypertension should be in line with NICE NG136 whilst the local Surrey Heartlands hypertension guidelines are being updated (https://surreyccg.res-systems.net/PAD/Guidelines/Detail/4397)
Where metolozone is being prescribed, please take note of the important safety information below:
When initiating patients on metolazone the licensed, branded Xaqua preparation should be prescribed.
Any switch between products should take into account the difference in bioavailability between Xaqua and other available unlicensed products.
Switching from the unlicensed (imported) product to Xaqua may require a reduction in dose by half, or for the same dose to be used but adjust the frequency from daily to alternate days.
The tablets have a single score-line and can be divided into equal halves.
The Medicines Safety Committee is leading ongoing work with local specialists around the review of patients currently prescribed unlicensed metolozane. Where there is any doubt about the intended product, please consult the specialist for advice.